More News! 18 Jul 2022 Purespring Therapeutics and SwanBio Therapeutics announce agreement for use of FunSel screening platform A licensing agreement for use of the FunSel screening platform has been announced by Purespring Therapeutics and SwanBio. Under the terms of the agreement, SwanBio will license the FunSel screening platform from Purespring to explore new targets for early-stage pipeline programs. SwanBio will have the option to develop any targets identified and to own and […] July 18, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Ginkgo Bioworks to collaborate with Sumitomo Chemical on animal-free personal care ingredient Cell programming company Ginkgo Bioworks has launched a new cell programming project as part of a broader collaboration with Japanese company Sumitomo Chemical Co., Ltd. Through the partnership, Sumitomo Chemical will leverage Ginkgo’s codebase and expertise in organism engineering to produce molecules in a sustainable way for products across a broad range of industries. The […] July 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Trial for drug targeting cancerous tumors begins in China A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Oxford Science Enterprises raises £250M Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its partnership with the University of Oxford, has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million ($1 billion) since inception in 2015. These funds […] July 18, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 First-ever Marketing Authorization Application for biosimilar targeting MS filed An international biotech, with headquarters in Amsterdam, has announced that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for its biosimilar product. Polpharma Biologics, which is dedicated to the development of biosimilars, announced on Friday (July 15) that natalizumab, similar to Tysabri, which treats multiple sclerosis, has been accepted as […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Enterome and Nestlé Health Science to work on food allergies and inflammatory bowel disease Enterome, a clinical stage biopharmaceutical company developing immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, has signed a strategic R&D collaboration and license agreement with Nestlé Health Science targeting food allergies and inflammatory bowel disease (IBD). The collaboration aims to develop and commercialize Enterome’s lead EndoMimics pipeline candidate EB1010. EB1010 is a local […] July 18, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jul 2022 Triastek forms pact with Eli Lilly to 3D print tablets for oral drug delivery A new research collaboration between Triastek, Inc. and Eli Lilly and Company will leverage 3D printing technology to achieve precise targeting and programmed drug release in the intestine. The China-based Triastek has developed proprietary 3D printing technology that provides solutions for drug development. According to the agreement, Triastek and Lilly will focus on improving the […] July 15, 2022 - 3 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jul 2022 European biotech stock woes continue but recovery hope remains European biotech stocks continue to disappoint, with half of listed biotechs in the region having just 12 months of cash left. However, a recent report from Bryan, Garnier & Co sees a strong biotech venture capital scene and rallying stocks as reasons to be optimistic. Biotech stocks have performed poorly in the last year as […] July 15, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jul 2022 Oncoshot raises cash to speed up clinical trial enrolment with AI The Singapore-based startup Oncoshot has raised an undisclosed amount in a pre-Series A round to drive the expansion of its artificial intelligence (AI)-driven clinical trial enrolment technology into Australia and India. The round, led by the tech-focused venture capital firm MassMutual Ventures, allows Oncoshot to pursue its mission of eliminating barriers to the recruitment of […] July 15, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jul 2022 WHO and UNICEF sound the alarm as global vaccination coverage continues to decline Amid worldwide disruptions caused by the COVID-19 pandemic, WHO and UNICEF report the largest continued backslide in childhood vaccinations in approximately three decades, with 25 million infants missing out on lifesaving vaccines in 2021 alone. It was hoped that the cohort of children that missed their vaccinations in 2020 would be caught up in 2021, […] July 15, 2022 - 4 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022Beyond Biotech podcast 5: ANeuroTech, ISA Pharmaceuticals, Life Length This week’s guests are Erik Buntinx, CEO and founder of ANeuroTech; Stephen J. Matlin, CEO of Life Length; and Kees Melief, chief scientific officer at ISA Pharmaceuticals. ISA Pharmaceuticals’ clinical trial using AMPLIVANT technology A clinical trial using ISA Pharmaceuticals’ AMPLIVANT adjuvant technology started in April. The trial, run by partner Scancell Holdings plc is […] July 14, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Boston startup bags $40M Series A to smash preclinical bottlenecks The U.S. company Manifold Bio has raised $40 million in a Series A round to bankroll protein barcoding technology that could speed up the preclinical development of targeted cancer drugs. Two years after bagging a $5.4 million seed investment, the Boston-based protein drug developer Manifold Bio has hit the headlines with a $40 million round […] July 14, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email